Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
3.7100-0.0400 (-1.07%)
As of 02:17PM EDT. Market open.
Currency in CAD

Valuation measures4

Market cap (intra-day) 133.58M
Enterprise value 115.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)7.84
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.62

Trading information

Stock price history

Beta (5Y monthly) 1.40
52-week change 3-25.00%
S&P500 52-week change 325.65%
52-week high 39.1000
52-week low 33.6700
50-day moving average 35.5148
200-day moving average 36.4100

Share statistics

Avg vol (3-month) 361.71k
Avg vol (10-day) 369.58k
Shares outstanding 535.62M
Implied shares outstanding 635.62M
Float 822.88M
% held by insiders 17.52%
% held by institutions 112.26%
Shares short (15 Mar 2024) 4101.37k
Short ratio (15 Mar 2024) 41.12
Short % of float (15 Mar 2024) 40.45%
Short % of shares outstanding (15 Mar 2024) 40.28%
Shares short (prior month 15 Feb 2024) 4810.37k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-57.17%
Return on equity (ttm)-205.97%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -29.98M
Net income avi to common (ttm)-34.41M
Diluted EPS (ttm)-1.5300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)33.21M
Total cash per share (mrq)1.22
Total debt (mrq)15.41M
Total debt/equity (mrq)102.34%
Current ratio (mrq)1.75
Book value per share (mrq)0.62

Cash flow statement

Operating cash flow (ttm)-25.09M
Levered free cash flow (ttm)-15.29M